Best Nephrology Companies in United States
The 109 best Nephrology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Outset Medical.
Ranked by disclosed equity funding and recent momentum, the 109 Nephrology companies tracked across the United States have pulled in $3.6 billion in total disclosed funding, and the spread between leaders tells you everything about where capital conviction actually sits. Outset Medical leads at $458 million raised, a figure that dwarfs the next tier by a wide margin. Arthrosi Therapeutics follows at $140 million, then Calyxo at $83 million. So the top three alone account for a disproportionate share of the pool, while most of the 109 sit well below $25 million, including VenoStent at $23 million and Secretome Therapeutics at $22 million. No unicorns have emerged yet, which means the sector's building mass without the valuation inflation that tends to distort other health tech categories.
The thematic heat right now clusters around diabetes and kidney disease, specifically diabetes kidney protection, dialysis access, and renal diet management, as shown by the direction recent clinical reporting is taking, including new findings on cognitive impairment and CKD outcomes that are sharpening urgency around earlier intervention. I'd note that coverage overall is flat, which means the opportunity for differentiated companies to stand out is real. Active investors like Foresite Capital and Delphi Ventures are already placing bets. If you're mapping this space, the funding concentration and the diabetes-renal nexus are the two coordinates worth anchoring to first.
Ranked: Best Nephrology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Outset Medical Provider of hemodialysis machine with touchscreen display | $458M | 17 mo ago | 372 372 → 567 (+52%) | Leslie Trigg Chief Executive Officer | WordPressMySQLPHP+27 | 3 signals ▼91% Earnings | — | 1 partnership |
| 2 | Peloton Therapeutics Developer of small molecule therapeutics to treat kidney cancer | $243M | 88 mo ago | 62 | Steven McKnight Co-Founder | — | — | 150 patents Develops small-molecule oncology drugs targeting HIF-2α, Hippo pathway, and novel scaffolds. | — |
| 3 | Relypsa Developer of drugs for treating cardiovascular and renal diseases | $208M | 121 mo ago | 284 | — | — | — | 270 patents Patents concentrated in health & consumer products | — |
| 4 | Astute Medical Pioneering diagnostics to improve global health through innovative solutions | $207M | 114 mo ago | 51 | — | — | — | 769 patents Renal injury biomarkers and diagnostic/therapeutic assays for acute kidney disease | 1 launch · 1 award |
| 5 | Chinook Therapeutics Developer of therapeutics for treating kidney diseases | $180M | 70 mo ago | 138 | Eric Dobmeier CEO & President | — | — | — | — |
| 6 | Renibus Therapeutics Provider of therapeutics to treat kidney diseases | $154M | 36 mo ago | 19 | Jeff Keyser Co-Founder | WordPressMySQLPHP+19 | — | — | — |
| 7 | Tricida Therapeutics for complications of Chronic Kidney Disease (CKD) | $153M | 86 mo ago | 26 | — | — | — | 221 patents Oral proton-binding polymer formulations for treating acid‑base and metabolic acidosis disorders | — |
| 8 | Judo Bio Developer of therapeutics for systemic and renal diseases | $150M | 20 mo ago | — | Rajiv Patni CEO | WordPressMySQLPHP+15 | — | — | 1 job opening |
| 9 | Keryx Biopharmaceuticals Markets ferric citrate for the treatment chronic kidney disease. | $146M | 128 mo ago | 142 | — | — | — | 112 patents Oral ferric citrate formulations for iron supplementation in chronic kidney disease patients | — |
| 10 | Arthrosi Therapeutics Developer of therapeutics for gout, chronic kidney diseases, and oncology 22Funding top 26%News top 46%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 26% Newstop 46% Moattop 48% Talentbottom 49% Techbottom 43% Globalbottom 37% Marketbottom 24% Funding: Raised $140M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) News: 2 BI events in 12 mo (of 6 tracked, 3 types) · +100% YoY rank vs industry peers · Fliar Intelligence Index 22/100 | $140M | 12 mo ago | 11 | Litain Yeh Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+24 | — | — | — |
| 11 | Affymax Drug for treatment of chronic kidney disease | $131M | 207 mo ago | 72 | — | — | — | 162 patents Erythropoietin receptor agonist peptides and PEGylated peptide drug delivery technologies | — |
| 12 | Alltrna Developer of tRNA medicines for various therapeutic areas | $109M | 34 mo ago | 46 46 → 48 (+4%) | Theonie Anastassiadis Co-Founder | — | — | — | — |
| 13 | Allena Developer of protein therapeutics to treat nephrology and urological conditions | $96M | 68 mo ago | 21 | Lou Brenner CEO | — | — | 3 patents Quantitative analytical methods for antibiotics and calicheamicin in bone tissue | — |
| 14 | Akebia Therapeutics Developing therapeutics solutions to treat patients with kidney disease | $91M | 28 mo ago | 205 205 → 264 (+29%) | John Butler President and CEO | WordPressApple iCloud MailMySQL+23 | 11 signals Announcements · Earnings | 539 patents Therapeutic small‑molecule drugs for anemia, complement inhibition, and related disease treatments | — |
| 15 | Sorbent Therapeutics Trusted Australian brand providing soft, strong, and sustainable tissue products | $91M | 145 mo ago | — | Don Joseph CEO | ShopifyYouTubeShop Pay+12 | — | — | — |
| 16 | MediBeacon Innovating fluorescent technology for improved patient care and disease management | $86M | 33 mo ago | 25 | Richard Dorshow Co-Founder & CSO | — | — | 333 patents Patents concentrated in health & consumer products | — |
| 17 | Calyxo Standalone nephrology hospital 69Funding top 19%Patents top 24%News top 25%Innovation top 31% All 9 signals ▾Fundingtop 19% Patentstop 24% Newstop 25% Innovationtop 31% Techtop 44% Moattop 44% Talentbottom 49% Marketbottom 47% Globalbottom 42% Funding: Raised $82.7M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 51 patents matched (strict assignee match) · 34 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $83M | 2 mo ago | 48 | Joe Catanese President & CEO | WordPress Block EditorwpBakeryWordPress+35 | 4 signals Funding · Capital raise | 51 patents Minimally invasive urological devices for kidney stone aspiration, irrigation, and catheter steering | 1 award |
| 18 | Diality Developer of portable hemodialysis device | $82M | 34 mo ago | 40 | Osman Khawar CEO | WebflowApple iCloud MailSalesforce+15 | — | 102 patents Advanced hemodialysis devices with precise fluid control, sensors, and disposable cartridges | — |
| 19 | KBP BioSciences Innovating therapies for unmet medical needs in hypertension, cardiorenal, and infectious diseases | $76M | 101 mo ago | 37 | — | BootstrapApache HTTP ServerjQuery UI+7 | — | — | — |
| 20 | Potrero Medical Critical care fluid monitoring device to detect Acute Kidney disease(AKD) and Sepsis | $76M | 19 mo ago | 74 74 → 39 (-47%) | — | — | — | — | — |
| 21 | Ceptur Therapeutics Developer of oligonucleotide therapeutics for the treatment of cancer | $75M | 53 mo ago | 6 | Samuel Gunderson Co-Founder | — | — | — | — |
| 22 | Angion Biomedica Developer of organ restoration therapies with a focus on renal diseases | $74M | 71 mo ago | 71 | Jay Venkatesan CEO | — | — | 228 patents Pharmaceutical solid forms and kinase/CYP450 inhibitor drugs for transplant and IBD | — |
| 23 | KAI pharmaceutical Novel peptide for the treatment of SHPT in patients with chronic kidney disease | $61M | 241 mo ago | 23 | — | — | — | — | — |
| 24 | Ardelyx Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases | $61M | 47 mo ago | 37 | Peter G Schultz Co-Founder | DrupalPHPTailwind CSS+20 | 17 signals ▼43% Earnings · Leadership · Announcements | 410 patents Oral phosphate transport inhibitors and formulations for kidney disease and hyperkalemia | 1 job opening · 1 internship |
| 25 | Walden Developer of drugs for the treatment of chronic kidney diseases | $51M | 68 mo ago | 26 | Blaine Mckee President and Chief Executive Officer | — | — | — | — |
| 26 | Ilypsa Develops phosphate and potassium binder compounds to treat chronic kidney diseases | $36M | 251 mo ago | 79 | — | — | — | 184 patents Pharmaceutical sodium-binding polymer compositions for drug delivery and therapeutic kits | — |
| 27 | Vascular Pharma Pioneering diabetes treatments, focusing on diabetic nephropathy and improving patient lives | $35M | 125 mo ago | 2 | — | — | — | — | — |
| 28 | VenoStent Developer of a shape memory polymer stent for vascular surgery | $23M | 2 mo ago | 18 | Timothy Boire President and CEO | — | — | 15 patents 3D‑printed photocrosslinkable vinyl polymers for vascular grafts and perivascular wraps | — |
| 29 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | 8 | Sudhish Sharma Co-Founder | WordPressMySQLPHP+14 | — | — | — |
| 30 | FAST BioMedical Fluorescent in-vivo markers to measure plasma volume and mGFR | $22M | 90 mo ago | 2 | — | — | — | 26 patents Quantitative biomedical diagnostics using fluorescent markers and blood/renal volume measurement. | — |
| 31 | NovaFlux Technologies Innovating healthcare through advanced medical device technologies and infection control | $20M | 9 mo ago | — | Mohamed Labib Founder & CEO | WixSentryEnvoy+12 | — | 77 patents Polymer-based oral care cleaning agents and drug‑release devices for membrane therapies | — |
| 32 | Nephros Water filtration solutions for medical and commercial markets, ensuring water quality | $19M | 69 mo ago | 27 | — | WordPress Block EditorWordPressMySQL+21 | 7 signals ▼53% Announcements · Earnings · Leadership | 143 patents Advanced flushable water filtration and rapid pathogen detection technologies for medical and environmental applications | — |
| 33 | Lisata Developer of therapeutics for cancer and vascular disorders | $15M | 71 mo ago | 27 | — | DrupalPHPSalesforce+22 | 5 signals Earnings · M&A · Contracts | — | — |
| 34 | Simergent Manufacturer of automated peritoneal dialysis system | $11M | 26 mo ago | 8 | — | — | — | 24 patents Automated peritoneal dialysis systems with customizable dialysate delivery | — |
| 35 | Cellvie Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney… | $10M | 9 mo ago | 12 | Alexander Schueller Founder & CEO | BootstrapNginxjQuery+2 | — | 10 patents Optimizing adoptive cell therapy by generating enhanced immune cell populations for immunotherapy | — |
| 36 | Rediscovery Life Sciences Developing drugs for treating acute kidney injury | $9M | 38 mo ago | 4 | — | — | — | — | — |
| 37 | Avvio Medical Developer of non-invasive treatments for patients with urinary stone diseases | $7M | 20 mo ago | — | Paul Watt Co-Founder & Chief Scientific Officer | WordPressMySQLPHP+18 | — | — | — |
| 38 | Oxalo Therapeutics Developing innovative therapeutics for rare kidney diseases and recurrent kidney stones | $7M | 16 mo ago | 2 | Hatim Hassan Co-Founder | — | — | — | — |
| 39 | Rila Therapeutics Provider of therapeutics for the treatments for kidney fibrosis | $7M | 18 mo ago | — | John He Co-Founder | — | — | — | — |
| 40 | ZyVersa Developer of therapies for treating renal and anti-inflammatory diseases | $6M | 50 mo ago | 7 | — | DrupalPHPZURB Foundation+21 | — | — | — |
| 41 | Mitotherapeutix Developer of small molecules based drug using siRNA technology for various diseases | $5M | 15 mo ago | 5 | Robert Hemley Co-Founder & COO | — | — | 8 patents Targeted multivalent ligand drug delivery and epigenetic J‑protein expression inhibition | — |
| 42 | US kidney Research Developer of artificial kidney for dialysis patients | $4M | 21 mo ago | 15 | Roland Ludlow CEO | — | — | — | — |
| 43 | NephroDI Therapeutics Developer of therapeutics for concentration disorders of the kidney | $4M | 24 mo ago | 5 | Ish Khanna Co-Founder | — | — | — | — |
| 44 | Astek Diagnostics Manufacturer of blood test diagnostic device | $3M | 26 mo ago | 8 | — | Node.jsFirebaseVuetify+7 | — | — | — |
| 45 | Reliant Glycosciences Developer of diagnostic assays for chronic kidney disease | $2M | 24 mo ago | 4 | Dana Rizk Co-Founder | Cart FunctionalityShopifySentry+11 | — | — | — |
| 46 | Eliaz Therapetuics Pioneering device to remove Galectin-3, addressing sepsis and related diseases | $2M | 14 mo ago | 5 | — | Framer SitesYouTubeReact+8 | — | — | — |
| 47 | Unicycive Developer of small molecule therapies for the treatment of kidney diseases | $2M | 27 mo ago | 12 12 → 24 (+100%) | — | WordPress Site EditorWordPressMySQL+23 | 4 signals ▼33% Earnings | — | 1 award |
| 48 | OLI Technologies Provider of wearable dialysis devices for kidney disease treatment | $700K | 16 mo ago | — | Thomas Weindl Co-Founder & CEO | — | — | — | — |
| 49 | Helex Provider of next-generation gene-editing therapies | $250K | 7 mo ago | 22 | Anirudh Nishtala Co-Founder & COO | WebflowSentryWistia+10 | — | 8 patents Lipid nanoparticle delivery systems for tissue-specific CRISPR gene editing therapies. | — |
| 50 | Praetego Developer of therapies to treat acute kidney injury, brain injury, and diabetic peripheral neuropathy | $120K | 15 mo ago | 1 | — | — | — | 12 patents Therapeutic peptides and heterocyclic compounds for neurodegenerative disease and AGE inhibition | — |
Top 12 Nephrology companies in United States
#1
Series F · Pleasanton, California · founded 2016 · 48 employees$82.7Mraised▾
Standalone nephrology hospital
- Apr 2026Series F$40.1M
- Dec 2024Series D$28.3M
- Oct 2023Series D$50M
- Feb 2022Series C$32.7M
#2
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
#3
Series A · Nashville, Tennessee · founded 2017 · 18 employees$22.8Mraised▾
Developer of a shape memory polymer stent for vascular surgery. The SelfWrap, is an external stent, used for venous access in hemodialysis patients. The stent, is a polymer wrap, provides a mechanical support and reduces vein collapse, at the point of surgery, by promoting vein growth in dialysis patients.
- Apr 2026Series A$10M
- May 2025Grant (prize money)$2.5M
- Apr 2025Grant (prize money)$2.5M
- Jun 2024Series A$4M
#4
Public · San Jose, California · founded 2003 · 372 employees$457.9Mraised▾
Provider of hemodialysis machine with touchscreen display. The company's product "Tablo" is a hemodialysis machine with a touchscreen display, which offers step-by-step pictures and conversational instructions.
- Jan 2025Post IPO$3.9M
- Feb 2020Series E$125M
- Aug 2018Series D$132M
- Jun 2017Series C$4.3M
#5
Acquired · Irvine, California · founded 2017 · 11 employees$140Mraised▾
Developer of therapeutics for gout, chronic kidney diseases, and oncology. The company's proprietary drug candidate includes AR882 which is used to decrease the level of uric acid in gout patients. It works by inhibiting urate transporter 1 (URAT1), an influx transporter protein present in kidneys.
- Jun 2025Series E$153M
- Jul 2023Series D$75M
- Mar 2023Series B$15M
- Nov 2021Series B$26M
#6
Funding Raised · Princeton, New Jersey · founded 1988$19.7Mraised▾
Innovating healthcare through advanced medical device technologies and infection control. The company is dedicated to pioneering new solutions in healthcare, focusing on infection control and dialysis therapies. They develop and commercialize medical devices using Two-Phase Flow technology and micro-structured fluids. Their innovations include biofilm removal, dialyzer reprocessing, and drug delivery systems. The company aims to improve patient outcomes and reduce healthcare costs. They are involved in research and development, creating intellectual property and licensing technologies. Their work has applications in diverse surgical areas. They are committed to pushing boundaries and making a difference in the healthcare industry.
- Sep 2025Grant (prize money)—
- Feb 2025Grant (prize money)$3M
- Jan 2025Grant (prize money)—
- Mar 2023Grant (prize money)$2M
#7
Series A · Cambridge, Massachusetts · founded 2021$150Mraised▾
Developer of therapeutics for systemic and renal diseases. It offers oligonucleotide medicines that enable receptor-mediated uptake of oligonucleotides to specific kidney cell types using proprietary ligand-siRNA conjugate that results in gene silencing of disease-modifying target genes.
- Oct 2024Series A$100M
- Jul 2024Series A$25M
- May 2024Series A$5M
- Nov 2022Series A$20M
#8
Seed · Houston, Texas · founded 2020 · 12 employees$10.5Mraised▾
Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation. The company has developed cell-based medicines by using the therapeutic potential of mitochondria. Its proprietary technology generates chemical energy by using the cell's biochemical reactions that help in the treatment of ischemia-reperfusion injury or reoxygenation injury.
- Sep 2025Seed$5M
- Feb 2023Seed$5.5M
- Jan 2021Seed$5M
- Sep 2020Grant (prize money)—
#9
Series C · San Francisco, California · founded 2011 · 74 employees$75.9Mraised▾
Potrero Medical is a privately held medical device company focused on commercializing its product Accuryn, which is a critical care monitoring system used to provide accurate fluid monitoring to detect and prevent Acute kidney injury and Sepsis. In 2016, Potrero Medical recieved FDA clearence for Accuryn. The Accuryn device consists of a urrinary catheter that measures urine output in real-time.
- Oct 2024Series C$3.2M
- Apr 2023Series C$17.7M
- Oct 2019Series C$17.2M
- Jul 2018Series C$26.6M
#10
Funding Raised · Chicago, Illinois · founded 2017 · 2 employees$7.4Mraised▾
Developing innovative therapeutics for rare kidney diseases and recurrent kidney stones. The company is focused on addressing unmet needs in renal health, particularly concerning oxalate-related pathologies. Their primary focus is on primary hyperoxaluria, a rare genetic liver disease leading to excessive oxalate production, kidney stone formation, and potential kidney failure. They are pioneering first-in-class peptide therapeutics inspired by the gut microbiome's natural oxalate-regulating mechanisms. This innovative approach aims to replicate the function of Oxalobacter formigenes to restore oxalate homeostasis. The company is committed to providing solutions for severe and rare kidney diseases, improving patient outcomes and quality of life. This is a B2B healthcare and pharmaceutical company.
- Feb 2025Grant (prize money)$2.3M
- Jul 2019Grant (prize money)$225K
- Sep 2018Grant (prize money)$2.3M
- Sep 2018Grant (prize money)$2.3M
#11
Funding Raised · Farmington, Connecticut · founded 2014 · 5 employees$5.2Mraised▾
Mitotherapeutix is a developer of small molecules based drug-using siRNA technology for various diseases. The company target and control the metabolic activity in the mitochondria helping in the treatment of kidney, immune, and liver diseases. The company drug candidates MT-001 to MT004 are in the early stage of the preclinical study. The company is targeting diseases like Unilateral Ureter Obstruction, acute liver failure, CD8 T-cells, and its role in treating diseases like cancer among others. The company is using proprietary technology to target the beta-oxidation pathway in the mitochondria.
- Mar 2025Grant (prize money)$30.9K
- Jan 2025Grant (prize money)$2.1M
- Apr 2023Grant (prize money)$273.9K
- Jun 2021Grant (prize money)$2.1M
#12
Public · Cincinnati, Ohio · founded 2007 · 205 employees$91Mraised▾
Developing therapeutics solutions to treat patients with kidney disease. The company's lead candidate is Vafseo is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
- Jan 2024Conventional Debt$55M
- Jun 2013Series C$41M
- Apr 2011Series B$22M
- Feb 2011Grant (prize money)$876K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Nephrology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.